Milestone Pharmaceuticals Inc. Operating Cash Flow
Milestone Pharmaceuticals Inc. (MIST) reported Operating Cash Flow of -$38.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.71M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$16.05M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$12.78M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.75M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$49.04M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$28.85M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$46.42M.
- Milestone Pharmaceuticals Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$52.47M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$38.77M 10-Q · filed 2026-08-12 | -$51.54M derived: sum of 3 quarters · filed 2026-08-12 | -$61.29M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$16.05M 10-Q · filed 2026-05-13 | -$28.83M derived: sum of 2 quarters · filed 2026-05-13 | -$38.58M derived: sum of 3 quarters · filed 2026-05-13 | -$51.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$12.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | -$22.52M derived: sum of 2 quarters · filed 2026-03-20 | -$35.09M derived: sum of 3 quarters · filed 2026-08-12 | -$49.04M 10-K · filed 2026-03-20 |
| 2025-09-30 | -$9.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$22.31M derived: sum of 2 quarters · filed 2026-08-12 | -$36.27M 10-Q · filed 2025-11-12 | -$43.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$12.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$26.52M 10-Q · filed 2026-08-12 | -$33.36M derived: sum of 3 quarters · filed 2026-08-12 | -$40.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$13.95M 10-Q · filed 2026-05-13 | -$20.80M derived: sum of 2 quarters · filed 2026-05-13 | -$27.81M derived: sum of 3 quarters · filed 2026-05-13 | -$33.87M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | -$13.86M derived: sum of 2 quarters · filed 2026-03-20 | -$19.91M derived: sum of 3 quarters · filed 2026-03-20 | -$28.85M 10-K · filed 2026-03-20 |
| 2024-09-30 | -$7.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$13.07M derived: sum of 2 quarters · filed 2025-11-12 | -$22.00M 10-Q · filed 2025-11-12 | -$31.80M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$14.99M 10-Q · filed 2025-08-12 | -$24.78M derived: sum of 3 quarters · filed 2025-08-12 | -$36.94M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$8.93M 10-Q · filed 2025-05-14 | -$18.73M derived: sum of 2 quarters · filed 2025-05-14 | -$30.89M derived: sum of 3 quarters · filed 2025-05-14 | -$41.45M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$21.96M derived: sum of 2 quarters · filed 2025-03-13 | -$32.52M derived: sum of 3 quarters · filed 2025-03-13 | -$46.42M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$12.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$22.72M derived: sum of 2 quarters · filed 2024-11-12 | -$36.63M 10-Q · filed 2024-11-12 | -$49.49M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$10.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$24.47M 10-Q · filed 2024-08-08 | -$37.33M derived: sum of 3 quarters · filed 2024-08-08 | -$48.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$13.90M 10-Q · filed 2024-05-13 | -$26.77M derived: sum of 2 quarters · filed 2024-05-13 | -$38.34M derived: sum of 3 quarters · filed 2024-05-13 | -$52.42M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$12.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$24.43M derived: sum of 2 quarters · filed 2024-03-21 | -$38.52M derived: sum of 3 quarters · filed 2024-03-21 | -$52.47M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$11.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$25.66M derived: sum of 2 quarters · filed 2023-11-13 | -$39.61M 10-Q · filed 2023-11-13 | -$51.98M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$14.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$28.03M 10-Q · filed 2023-08-10 | -$40.41M derived: sum of 3 quarters · filed 2023-08-10 | -$49.80M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.95M 10-Q · filed 2023-05-11 | -$26.33M derived: sum of 2 quarters · filed 2023-05-11 | -$35.72M derived: sum of 3 quarters · filed 2023-05-11 | -$34.70M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$21.77M derived: sum of 2 quarters · filed 2023-03-29 | -$20.75M derived: sum of 3 quarters · filed 2023-03-29 | -$33.22M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$9.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$8.38M derived: sum of 2 quarters · filed 2022-11-10 | -$20.85M 10-Q · filed 2022-11-10 | -$29.60M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$11.46M 10-Q · filed 2022-08-10 | -$20.21M derived: sum of 3 quarters · filed 2022-08-10 | -$27.55M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$12.47M 10-Q · filed 2022-05-12 | -$21.23M derived: sum of 2 quarters · filed 2022-05-12 | -$28.56M derived: sum of 3 quarters · filed 2022-05-12 | -$45.12M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$16.09M derived: sum of 2 quarters · filed 2022-03-24 | -$32.65M derived: sum of 3 quarters · filed 2022-03-24 | -$50.73M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$7.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$23.90M derived: sum of 2 quarters · filed 2021-11-12 | -$41.98M 10-Q · filed 2021-11-12 | -$58.58M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$16.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$34.64M 10-Q · filed 2021-08-11 | -$51.24M derived: sum of 3 quarters · filed 2021-08-11 | -$59.54M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$18.08M 10-Q · filed 2021-05-17 | -$34.68M derived: sum of 2 quarters · filed 2021-05-17 | -$42.98M derived: sum of 3 quarters · filed 2021-05-17 | -$54.50M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$16.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$24.90M derived: sum of 2 quarters · filed 2021-03-29 | -$36.42M derived: sum of 3 quarters · filed 2021-03-29 | -$51.15M 10-K · filed 2021-03-29 |
| 2019-09-30 | -$8.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$19.82M derived: sum of 2 quarters · filed 2020-11-13 | -$34.55M 10-Q · filed 2020-11-13 | -$41.86M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | -$11.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$26.25M 10-Q · filed 2020-08-12 | -$33.56M derived: sum of 3 quarters · filed 2020-10-23 | -$39.15M derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | -$14.73M 10-Q · filed 2020-05-14 | -$22.04M derived: sum of 2 quarters · filed 2020-10-23 | -$27.64M derived: sum of 3 quarters · filed 2020-10-23 | -$31.06M derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | -$7.31M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | -$12.90M derived: sum of 2 quarters · filed 2020-10-23 | -$16.32M derived: sum of 3 quarters · filed 2020-10-23 | -$21.05M 10-K/A · filed 2020-10-23 |
| 2018-09-30 | -$5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$9.01M derived: sum of 2 quarters · filed 2019-11-13 | -$13.73M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$8.14M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | -$4.72M 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |